BioTime to Present at the Raymond James 39th Annual Institutional Investor Conference

BioTime, Inc. BTX, a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of BioTime, will be presenting at the Raymond James 39^th Annual Institutional Investor Conference on Wednesday, March 7, 2018 at 10:25am ET, at the J.W. Marriott Grande Lakes Hotel.

Mr. Skibsted will also be meeting with investors throughout the conference. One-on-one meetings with Mr. Skibsted may be scheduled through the Raymond James 1x1 desk or by contacting David Nakasone, Director of Investor Relations at BioTime, at 510-871-4188 or dnakasone@biotime.com.

About The Raymond James 39th Annual Institutional Investors Conference

The Institutional Investors Conference, held annually in Orlando, Florida during the first week of March, is Raymond James' signature event. In 2017, the event featured over 300 companies and more than 900 institutional investors from the U.S., Canada and Europe.

About BioTime, Inc.

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: cell replacement and cell/drug delivery. With its cell replacement platform, BioTime is creating new cells and tissues with its proprietary pluripotent cell technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases. BioTime's cell/drug delivery programs are based upon its proprietary HyStem^® cell and drug delivery matrix technology. HyStem^® was designed to provide for the transfer, retention, engraftment and metabolic support of cellular replacement therapy. BioTime's lead cell delivery clinical program, Renevia^®, which consists of our proprietary HyStem^® cell-transplantation delivery matrix combined with the patient's own adipose progenitor cells (Fat), met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients in 2017. Submission for approval of Renevia^® in the EU is expected to be early 2018, with possible approval in 2018. There were no device related serious adverse events reported to date. Our lead cell replacement clinical program, OpRegen^®, which is a retinal pigmented epithelium transplant therapy, is in a Phase I/IIa multicenter trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. There were no related serious adverse events reported to date. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation OCX, and a private company, AgeX Therapeutics, Inc.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join the Company's email alert list: http://news.biotime.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180228005487/en/